<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083197</url>
  </required_header>
  <id_info>
    <org_study_id>START</org_study_id>
    <nct_id>NCT03083197</nct_id>
  </id_info>
  <brief_title>Scrub Typhus Antibiotic Resistance Trial</brief_title>
  <acronym>START</acronym>
  <official_title>The Scrub Typhus Antibiotic Resistance Trial (START) Comparing Doxycycline and Azithromycin Treatment Modalities in Areas of Reported Antimicrobial Resistance for Scrub Typhus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shoklo Malaria Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiangrai Prachanukroh Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study type: Randomized Control Treatment Trial

      Study population: Male and female patients with ≥15 years of age and acute scrub typhus

      Duration: 2 years

      Study Design: Prospective, open-label, randomized-controlled treatment trial in patients ≥15
      years old admitted to hospital with acute scrub typhus. Randomization into 3 oral treatment
      arms (each n=59 patients, total n=177): i) 7 days of doxycycline, ii) 3 days of doxycycline,
      and iii) 3 days of azithromycin

      Primary Objective: To evaluate the clinical and microbiological responses in scrub typhus
      patients to three oral treatment regimens: 7 days of doxycycline, 3 days of doxycycline, and
      3 days of azithromycin

      Secondary Objectives:

        1. To perform pharmacokinetic/pharmacodynamics (PK/PD) characterization of the therapeutic
           responses for doxycycline and azithromycin, incl. serial bacterial load measurements.

        2. To define clinical, bacterial, pathophysiological and pharmacological factors associated
           with disease severity, fever-clearance times (FCT), treatment failures and
           relapse/re-infection.

        3. To determine the minimum inhibitory concentrations (MIC) of clinical Orientia
           tsutsugamushi isolates to doxycycline, azithromycin and chloramphenicol, using in vitro
           growth-inhibition assays

        4. To genotype all clinical isolates using whole genome sequencing for comparative
           genomics.

        5. To dissect the natural immune response in scrub typhus, using antigen-specific cellular
           immune and antibody studies, and cytokine profiling
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fever clearance time (FCT)</measure>
    <time_frame>at least 24 hours</time_frame>
    <description>Based on the time from first dose of antibiotic treatment to when the tympanic temperature first falls ≤37.5°C and remains ≤37.5°C for at least 24 hours, outside of the influence of paracetamol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of bacteraemia in relation to Drug plasma level</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of severe disease or treatment failure/relapse</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of in vitro antimicrobial resistance</measure>
    <time_frame>8 Weeks</time_frame>
    <description>(Minimum inhibitory concentrations (MIC) over susceptibility cut off)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of clinical Orientia tsutsugamushi isolates (56kDa gene +/- whole genome sequencing)</measure>
    <time_frame>2 years</time_frame>
    <description>Genotyping of clinical OT isolates will be performed on patient samples that are PCR positive (approximately 50-60%) and/or culture positive (approximately 30%). Extracted DNA will be sent for 56kDa gene sequencing +/- whole genome sequencing, revealing the clinically important strains and allowing for comparative analysis with disease severity and patient outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antigen-specific positive cellular and humoral immune responses</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Scrub Typhus</condition>
  <arm_group>
    <arm_group_label>Doxycycline 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>loading dose 200mg PO, then 100mg PO every 12 hours for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>loading dose 200mg PO, then 100mg PO every 12 hours for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 7 days</intervention_name>
    <description>loading dose 200mg PO, then 100mg PO every 12 hours for 7 days</description>
    <arm_group_label>Doxycycline 7 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 3 days</intervention_name>
    <description>loading dose 200mg PO, then 100mg PO every 12 hours for 3 days</description>
    <arm_group_label>Doxycycline 3 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 3 days</intervention_name>
    <description>loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3</description>
    <arm_group_label>Azithromycin 3 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 15 years old

          -  Hospitalization with acute undifferentiated fever (temperature &gt; 37.5°C, tympanic) ≤14
             days or patients admitted to hospital with a history of fever ≤ 14 days who
             subsequently develop fever within 24 hours of admission

          -  Clinically suspected scrub typhus: defined as acute undifferentiated fever with no
             clear focus of infection and negative malaria blood smear and/or negative malaria RDT.
             Patients may have one, none, or a combination of other clinical findings such as
             eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal
             discomfort.

          -  A positive scrub typhus RDT (Scrub Typhus IgM RDT, InBios International, Seattle, WA,
             USA) and/or positive PCR-based detection of O. tsutsugamushi DNA from the admission
             blood sample

          -  Written informed consent and/or, written informed assent as required

          -  Able to take oral medication

        Exclusion Criteria:

          -  Known hypersensitivity to tetracycline, doxycycline or azithromycin

          -  Administration of doxycycline, azithromycin, chloramphenicol, rifampicin, or
             tetracycline during the preceding 7 days

          -  Pregnancy or breast-feeding

          -  Patients with myasthenia gravis or systemic lupus erythematosus

          -  Patients with an established infection (diagnostic test required) e.g. acute malaria,
             dengue, leptospirosis, typhoid, Japanese encephalitis etc.

          -  Current TB or TB treatment in ≤ 6 months (contain active antibiotics against Orientia
             spp.)

          -  Current HAART use for HIV, long term use of immunosuppressants (e.g. steroids,
             chemotherapy, TNF-inhibitors and related agents)

          -  Patients with severe disease whom the clinical team feel their condition necessitates
             the need for additional scrub typhus treatment beyond the allocated antibiotic
             treatment assigned at randomization (e.g. IV chloramphenicol and/or PO/NG rifampicin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assoc. Prof. Daniel Paris</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Assoc. Prof. Daniel Paris</last_name>
    <phone>+6622036373</phone>
    <email>parigi@tropmedres.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tri Wangrangsimakul</last_name>
    <phone>+6622036333</phone>
    <email>tri@tropmedres.ac</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shoklo-Malaria Research Unit (SMRU)</name>
      <address>
        <city>Mae Sot</city>
        <state>Tak</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rose McGready, Prof</last_name>
      <email>rose@shoklo-unit.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tri Wangrangsimakul, MD</last_name>
      <email>Tri@tropmedres.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scrub Typhus</keyword>
  <keyword>Antibiotic Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhus, Epidemic Louse-Borne</mesh_term>
    <mesh_term>Scrub Typhus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

